Literature DB >> 20219385

Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies.

Helen E Davies1, Jennie E Nicholson, Najib M Rahman, Emily M Wilkinson, Robert J O Davies, Yun Chor Gary Lee.   

Abstract

OBJECTIVE: Medical thoracoscopy is recommended in the investigation of patients with exudative pleural effusions, especially when pleural fluid analysis is uninformative. The histological finding of 'nonspecific pleuritis/fibrosis' is common in thoracoscopic biopsies and presents a great uncertainty for clinicians and patients as the long-term outcome of these patients is unclear, and anxieties about undiagnosed malignancy persist.
METHOD: A retrospective case-note study of 142 patients who underwent medical thoracoscopy over a 58-month period in a tertiary referral centre with a high incidence of mesothelioma. Patients with 'nonspecific pleuritis/fibrosis' were followed up until death or for a mean (±SD) period of 21.3 (±12.0) months.
RESULTS: A definitive histological diagnosis was achieved in 98 (69%) patients. A total of 44 (31%) patients had 'nonspecific pleuritis/fibrosis'. Five (12%) were subsequently diagnosed with malignant pleural disease after a mean interval of 9.8 (±4.6) months. All five patients had histologically confirmed mesothelioma. In 26 patients with 'nonspecific pleuritis/fibrosis', no cause for the pleural effusion was discovered. The false-negative rate of thoracoscopic biopsy for the detection of pleural malignancy was 5%, with a diagnostic sensitivity of 95% and negative predictive value of 90%. Pleural effusion recurrence was more frequently associated with a false-negative pleural biopsy result. However, there was no correlation with other patient characteristics or the thoracoscopist's prediction based on macroscopic appearances.
CONCLUSION: Thoracoscopic pleural biopsy is valuable in the diagnosis of pleural malignancies. Patients with 'nonspecific pleuritis/fibrosis' require follow-up as a malignant diagnosis (especially mesothelioma) may eventually be established in approximately 12% of cases.
Copyright © 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20219385     DOI: 10.1016/j.ejcts.2010.01.057

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  26 in total

Review 1.  Thoracoscopy: medical versus surgical-in the management of pleural diseases.

Authors:  Samira Shojaee; Hans J Lee
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

2.  The continual search for ideal biomarkers for mesothelioma: the hurdles.

Authors:  Fraser J Brims; Y C Gary Lee; Jenette Creaney
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

3.  Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion.

Authors:  Y Murata; K Aoe; Y Mimura-Kimura; T Murakami; K Oishi; T Matsumoto; H Ueoka; K Matsunaga; M Yano; Y Mimura
Journal:  Clin Exp Immunol       Date:  2017-07-17       Impact factor: 4.330

Review 4.  Medical thoracoscopy in China-the present status and the future.

Authors:  Jing-Yuan Liu; Liang Xiong; Min Zhang; Shi-Yuan Shuai; Xiao-Shan Wei; Lin-Lin Ye; Qiong Zhou
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

5.  Loculated transudative pleural effusion masquerading as right upper lobe consolidation in a haemodialysis patient.

Authors:  Sze Shyang Kho; Poh Sen Tay; Jun Lee; Siew Teck Tie
Journal:  AME Case Rep       Date:  2017-10-18

6.  Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions.

Authors:  Chun-Hua Xu; Ping Zhan; Li-Ke Yu; Xiu-Wei Zhang
Journal:  Tumour Biol       Date:  2013-09-26

Review 7.  Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.

Authors:  Seiki Hasegawa; Nobuyuki Kondo; Seiji Matsumoto; Teruhisa Takuwa; Masaki Hashimoto; Hayato Orui; Shunichi Fukuda; Kazue Yoneda; Yoshitomo Okumura; Noriaki Tsubota; Kazuya Fukuoka; Ikuko Torii; Tohru Tsujimura; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

8.  Evaluation of Exudative Pleural Effusions: A Multicenter, Prospective, Observational Study.

Authors:  Guntulu Ak; Selma Metintas; Ayse Naz Taskın; Melahat Uzel Sener; Yasemin Soyler; Meltem Yilmaz; Akif Turna; Pınar Akin Kabalak; Semra Bilaceroglu; Deniz Koksal; Nilgun Yilmaz Demirci; Ozlem Sogukpinar; Sibel Boga; Merve Ercelik; Gulistan Karadeniz; Gulru Polat; Filiz Guldaval; Ulku Aka Akturk; Senay Yilmaz; Nalan Ogan; Saliha Yilmaz; Dorina Esendagli; Benan Caglayan; Arife Zeybek; Nagihan Durmus Kocak; Pinar Mutlu; Cansel Atinkaya Baytemir; Ismail Sarbay; Ulku Yilmaz; Muzaffer Metintas
Journal:  Lung       Date:  2022-09-29       Impact factor: 3.777

9.  Use of circulating tumor cell technology (CELLSEARCH) for the diagnosis of malignant pleural effusions.

Authors:  Daniel E Schwed Lustgarten; Jeffrey Thompson; Gordon Yu; Anil Vachani; Bhavesh Vaidya; Chandra Rao; Mark Connelly; Michelle Udine; Kay See Tan; Daniel F Heitjan; Steven Albelda
Journal:  Ann Am Thorac Soc       Date:  2013-12

10.  Incidence of malignancy and survival in patients with idiopathic pleuritis.

Authors:  Simon Bertram Reuter; Paul Frost Clementsen; Uffe Bodtger
Journal:  J Thorac Dis       Date:  2019-02       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.